Für diesen Artikel ist leider kein Bild verfügbar.

Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy

Robert Musiol (Herausgeber)

Buch | Hardcover
200 Seiten
2023
Academic Press Inc (Verlag)
978-0-323-90197-0 (ISBN)
169,95 inkl. MwSt
Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy presents an in-depth and up-to-date compilation of research on isocitrate dehydrogenase as drug target to be used as a sensitizing agent in chemotherapy. The book brings a combination of medicinal, biological and chemical points-of-view to fully cover the subject. It discusses topics such as IDH place in cellular metabolism, mutant IDH as drug target, mono- and poli-therapies based on IDH1/2 inhibitors, and IDH1/2 inhibitors in leukemia, gliomas and other brain tumors, and potential importance in gastrointestinal cancers. Additionally, it discusses isocitrate dehydrogenases as target for theranostics, therapeutic strategies and future perspectives.

This is a valuable resource for cancer researchers, oncologists and members of the biomedical field who are interested to learn more about IDH inhibitors and their potential as sensitizing agents for chemotherapy.

Prof. Dr Robert Musiol received a PhD in organic chemistry in 2005 and habilitation in pharmacy in 2013. For roughly twenty years he is connected with University of Silesia in Katowice, Poland, where he teaches medicinal chemistry, pharmacology and toxicology. His scientific interest is focused on drug design and particularly polypharmacological design of potential anticancer drugs. Recently he is involved in redesign of IDH1 inhibitors towards multi-kinase activity. He is a co-author of more than one hundred scientific papers and thirty patents. Being involved in teaching and popularizing science, he was supervisor of four doctorates and more than forty master’s degree students.

1. Isocitrate dehydrogenase and its place in cellular metabolism
2. Wild type and mutant IDH as drug target
3. Holy grail of combination therapy? Possibilities and limitations of mono- and poli-therapies based on IDH1/2 inhibitors
4. Two faced IDH. The good and bad in prognosis
5. Inhibitors of IDH1/2 in leukemias
6. Inhibitors of IDH1/2 in gliomas and other brain tumors
7. Potential importance of IDH in gastrointestinal cancers
8. Isocitrate dehydrogenases as target for theranostics
9. Resistance emerging and therapeutic strategies
10. Challenges and future perspectives

Erscheint lt. Verlag 1.8.2023
Reihe/Serie Cancer Sensitizing Agents for Chemotherapy
Zusatzinfo 70 illustrations (40 in full color); Illustrations, unspecified
Verlagsort Oxford
Sprache englisch
Maße 191 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Naturwissenschaften Biologie
ISBN-10 0-323-90197-2 / 0323901972
ISBN-13 978-0-323-90197-0 / 9780323901970
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00
Resilienz innovativ stärken : ein Praxishandbuch

von Christa Diegelmann; Margarete Isermann; Tanja Zimmermann

Buch | Softcover (2023)
Kohlhammer (Verlag)
36,00